Invest in ME Research has now reached the target set for the B-cell/rituximab fund.
This is another major target reached and is a wonderful achievement by dedicated supporters and friends across the world. The total of funds raised or pledged for B-cell/rituximab projects is £520,000.
From this the charity has already funded research at UCL, including a PhD student, and allowed strong collaboration to be formed with the researchers at Haukeland University Hospital in Bergen, Norway.
The initial preliminary B-cell study at UCL looked for likely responders and also introduced the UCL team to research into ME, leading to a UK rituximab trial.
This early work also created the foundations of close collaboration between the UK team and the Norwegian researchers at Haukeland University Hospital in Bergen.
This working collaboration and the work performed at UCL was credited as enormously valuable to the Norwegian rituximab trial work by one of the specialists there.
To read the rest of this story, click on the link below: